Fulcrum Therapeutics Statistics Share Statistics Fulcrum Therapeutics has 54.09M
shares outstanding. The number of shares has increased by 0.28%
in one year.
Shares Outstanding 54.09M Shares Change (YoY) 0.28% Shares Change (QoQ) 0.21% Owned by Institutions (%) 82.22% Shares Floating 47.95M Failed to Deliver (FTD) Shares 381 FTD / Avg. Volume 0.05%
Short Selling Information The latest short interest is 3.69M, so 6.82% of the outstanding
shares have been sold short.
Short Interest 3.69M Short % of Shares Out 6.82% Short % of Float 9.84% Short Ratio (days to cover) 9.1
Valuation Ratios The PE ratio is -29.96 and the forward
PE ratio is -7.84.
Fulcrum Therapeutics's PEG ratio is
0.34.
PE Ratio -29.96 Forward PE -7.84 PS Ratio 3.64 Forward PS 1649.3 PB Ratio 1.2 P/FCF Ratio -116.72 PEG Ratio 0.34
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Fulcrum Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 22.63,
with a Debt / Equity ratio of 0.04.
Current Ratio 22.63 Quick Ratio 22.63 Debt / Equity 0.04 Debt / EBITDA -0.47 Debt / FCF -3.46 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.78M Profits Per Employee $-216.11K Employee Count 45 Asset Turnover 0.31 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 159.13% in the
last 52 weeks. The beta is 2.81, so Fulcrum Therapeutics's
price volatility has been higher than the market average.
Beta 2.81 52-Week Price Change 159.13% 50-Day Moving Average 7.23 200-Day Moving Average 5.44 Relative Strength Index (RSI) 77.56 Average Volume (20 Days) 719,333
Income Statement In the last 12 months, Fulcrum Therapeutics had revenue of 80M
and earned -9.72M
in profits. Earnings per share was -0.17.
Revenue 80M Gross Profit 78.41M Operating Income -21.9M Net Income -9.72M EBITDA -18.24M EBIT -19.83M Earnings Per Share (EPS) -0.17
Full Income Statement Balance Sheet The company has 58.21M in cash and 8.63M in
debt, giving a net cash position of 49.58M.
Cash & Cash Equivalents 58.21M Total Debt 8.63M Net Cash 49.58M Retained Earnings -519.4M Total Assets 228.84M Working Capital 210.39M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.22M
and capital expenditures -278K, giving a free cash flow of -2.5M.
Operating Cash Flow -2.22M Capital Expenditures -278K Free Cash Flow -2.5M FCF Per Share -0.04
Full Cash Flow Statement Margins Gross margin is 98.01%, with operating and profit margins of -27.37% and -12.16%.
Gross Margin 98.01% Operating Margin -27.37% Pretax Margin -12.16% Profit Margin -12.16% EBITDA Margin -22.8% EBIT Margin -27.37% FCF Margin -3.12%
